Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

In this trial, FLOT will be evaluated as therapy option for elderly patients (>65 years) with advanced gastric cancer in comparison to the well established FLO scheme. The hypothesis is that FLOT is more effective than FLO in elderly patients with acceptable side effects.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Krankenhaus Nordwest
• Treatments: Docetaxel; Fluorouracil; Folic Acid; Leucovorin; Levoleucovorin; Oxaliplatin

Criteria

Inclusion Criteria:

• metastatic or locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction

• no prior chemotherapy in metastatic state

• adequate blood and biochemistry parameters

Exclusion Criteria:

• hypersensitivity for 5-FU, Leucovorin, Oxaliplatin or Docetaxel

• KHK, cardiomyopathy or cardiac insufficiency

• malignancy <5 years ago

• brain metastases

• severe internal disease or inadequate blood and biochemistry parameters